Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune DiseasesMedia Release...
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
TUCSON, Ariz., Dec. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
$500 Million Upfront Payment to Activate the Partnership for IvonescimabMenlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06,...
Professor Dr. med. Matthias Dobbelstein Professor Dr. med. Matthias DobbelsteinJerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals...
BOULDER, Colo., Dec. 06, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation...
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more...
Matthew Hawryluk, Ph.D. POAI Board of DirectorsEAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is...
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted...
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with...
Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer...
REGULATED INFORMATION Appointment to further integrate BioSenic’s both cell therapy and autoimmune disease platforms under the responsibility of a new...
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting...
The International Myeloma Foundation will work with Amazon’s cloud computing arm to educate patients, understand donors, increase fundraising, and moreSTUDIO...
ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022WATERTOWN, Mass., Dec. 01, 2022 (GLOBE...
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib...
SAN MATEO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it received approval from the New...
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and...